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Role of Echocardiography in Tako-Tsubo Cardiomyopathy
Beyond Diagnosis?*John D. Horowitz, MBBS, BMEDSCI(HONS), PHD, Thanh H. Nguyen, MD, MMEDSCI, PHDAdelaide, AustraliaTako-tsubo cardiomyopathy (TTC) is characterized
by the acute onset of segmental systolic dysfunction
of regions of the left (and sometimes the right)
ventricle, associated with various degrees of chest
discomfort and/or dyspnea (1). Differentiating TTC
from acute myocardial infarction may present a
challenging task, requiring a combination of echo-
cardiography, cardiac catheterization, and subsequent
cardiac magnetic resonance (CMR) evaluation (2).See page 119Most TTC patients are aging women, and in most
cases, attacks are precipitated by severe physical or
emotional stress. It has become clear that an “aber-
rant” cardiac response to catecholamine stimulation
initiates TTC episodes: indeed, as TTC may also be
induced by medical administration of catecholamine,
there are some obvious therapeutic priorities associ-
ated with the diagnosis, even though the precise
signal transduction cascade initiated by catechol-
amine exposure remains only partially elucidated (3).
Furthermore, TTC is characterized by both
myocardial and systemic inﬂammatory activation,
demonstrable on CMR (4) and via “non-congestive”
release of B-type natriuretic peptide (BNP) (5).
There is increasing evidence that TTC is not
necessarily benign either in the short or long term.
Although the absolute risk of early life-threatening
tachyarrhythmia remains uncertain, it is clear that
many patients develop substantial hypotension in*Editorials published in JACC: Cardiovascular Imaging reﬂect the views
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contents of this paper to disclose.the ﬁrst 24 h after symptom onset. This may extend
to severe shock (6), although interestingly, in most
cases, without pulmonary edema. Previous small
studies have raised the possibility that severity of
TTC episodes and, in particular, the concomitant
presence of mitral regurgitation (MR), left ventric-
ular outﬂow tract obstruction (LVOTO), and extent
of right ventricular hypokinesis might contribute to
the probability of development of shock (Fig. 1)
(7,8). Importantly, the treatment of shock in TTC
represents a therapeutic dilemma, as catecholamine
administration, in theory, should be avoided. Lev-
osimendan has been suggested (9,10), although to
date, clinical data are limited. Also, some patients
have been treated via intra-aortic balloon pump
insertion. Despite this, there is a signiﬁcant (perhaps
3%) acute mortality rate associated with TTC,
largely due to unresponsive cases of shock.
In this issue of iJACC, Citro et al. (11) report the
results of a collaborative study carried out in 12
Italian centers, evaluating the potential utility of
echocardiography in the setting of acute heart fail-
ure/shock associated with TTC. A total of 227 TTC
patients were studied, of whom 45 developed early
heart failure, 18 developed cardiogenic shock, and
4 died of cardiac causes. The data showed that the
combination of heart failure/shock/subsequent
mortality was associated substantially with the
presence of moderate to severe MR (present in 49
patients) and that advanced age ($75 years of age)
also correlated strongly with these outcomes.
Importantly, MR was also signiﬁcantly associated
with the combination of shock and mortality.
Although the authors suggest that echocardio-
graphic parameters may have prognostic implica-
tions in TTC patients, this is, in reality, far from
clear cut. Speciﬁcally, the occurrence of shock is
almost always an early event in TTC, and thus,
shock could hardly be said to have been predicted by
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Figure 1. Mechanisms Postulated as Potential Components of Pathogenesis of Hypotension/Shock in TTC
Potential sites of modulation of hypotension, as summarized by Chong et al. (6), are indicated. E ¼ echocardiographic assessment.
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131the echocardiographic results; rather, the occurrence
of MR can be regarded as a potential contributor to
this complication. Interestingly, the precise cause(s)
of MR in TTC is uncertain. In the current study,
there was no obvious association with LVOTO
(which was not commonly seen) or with the extent of
LV dyskinesis or major site of LV hypokinesis.
In theory, given the recent demonstration of exten-
sive LV inﬂammation in TTC (4), inﬂammatory
dysfunction of papillary muscles also represents a
possible cause. The number of deaths in this study is
too small to be used to predict mortality per se.
It should be also emphasized that hypotension/
shock after TTC may reﬂect noncardiac factors such
as chronotropic incompetence and paradoxical pe-
ripheral vasodilatation (6). Nevertheless, the study by
Citro et al. (11) serves to alert us that the presence of
signiﬁcant MR in TTC patients is a substantial
contributor to hemodynamic crises in this condition.
Finally, we must resist the temptation to regard
the prevention and/or treatment of shock as the onlysigniﬁcant therapeutic challenge in patients with
TTC. There is now overwhelming evidence that
symptoms resolve slowly, with as many as 50% of
patients still symptomatic 2 years after an acute
attack (12), that inﬂammatory activation (4) and
BNP release (5) persist for at least 3 months, and
that there are subtle but detectable, residual anom-
alies of left ventricular systolic dysfunction at that
stage. Preliminary data (13) have suggested im-
pairment of myocardial energetics in TTC, but the
duration of this problem during recovery has not
been reported. Moreover, the long-term recurrence
rate of TTC is approximately 3% per annum (14).
Thus TTC, as both an acute and subacute disease
process, remains very much a work in progress.
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